Transforming biomanufacturing economics
Fit-for-purpose manufacturing systems that unlock commercial profitability for bio-made products.
The science is ready. The economics are not.
Synthetic biology can now make food proteins, fats and oils, fuels and countless other products. Yet after two decades of innovation, very few companies have crossed the Valley of Death.
Unblok Bio has a single mission: solve the bio-made cost problem.
Balance of plant, not the equipment, drives the capex
Piping, utilities, graded facilities, commissioning and IT/OT dominate what it costs to build a bio-plant, so cheaper vessels alone won't fix the economics.
of capex is equipment in a $500M cell-culture product plant
balance-of-plant spend relative to equipment spend
of spend goes to production readiness, not production itself
Four first-principles innovations, one target: 10x lower cost
Peer-to-peer transactional architecture
Mobile equipment connects directly through proprietary aseptic connectors, replacing fixed piping networks.
Attacks balance of plantPlug-n-play, software-defined process
Modular equipment in a warehouse-grade facility; the process is defined and changed in software.
Attacks time to capacityAI-native autonomous operation
One operating system schedules, dispatches and moves a mobile equipment fleet.
Attacks labor and IT/OTProprietary process intensification
Multi-stage continuous bioreactor for higher volumetric productivity.
Attacks productivityFrom fixed infrastructure to peer-to-peer transactions
We solve the connectivity problem once, so customers don't have to solve it again on every new project.
Conventional: fixed, stick-built infrastructure
- Utility distribution network
- CIP/SIP circuits
- Process piping network
- Clean room / graded suite
- Engineering, design & construction management
Unblok: stationary + mobile equipment, peer-to-peer
- Basic power, water and steam mains
- Project management
- Enabled by proprietary aseptic connection technology
Bench to industrial scale in months, not years
Modular equipment deployed in warehouse-grade facilities. New production capacity comes online in months, and the same equipment is reconfigured in software.
Unblok: Bench → Pilot 3–6 months · $2–5M. Pilot → Industrial 6–9 months · $30–80M.
One AI-native OS replaces the legacy plant software stack
- One non-hierarchical, cloud-centric architecture
- Orchestrates mobile production workflows end to end
- Intelligent scheduling, dispatching and on-the-fly rescheduling
- Autonomous moving and docking of the mobile equipment fleet
A multi-stage bioreactor for continuous production
3–5x
volumetric productivity vs. fed-batch
- One bioreactor integrating multiple connected stages
- Continuous, intensified cell or microbial culture
- Curb Warburg/Crabtree effects for ultra-high product yield
Spend shifts from production readiness to production
| Conventional | Unblok Bio | Cost impact |
|---|---|---|
| Stick-built installation | Plug-n-play deployment | 3–4x faster launch |
| Fixed piping network | Peer-to-peer transactions | 70–90% saving on balance of plant |
| Dedicated auxiliary equipment | Shared mobile equipment fleet | ~50% saving on equipment |
| Fed-batch | Intensified continuous process | 3–5x volumetric productivity |
| Complex dependencies | AI-native operating system | 60–80% saving on labor |
Product-agnostic: the same system works for most bio-made products.
The core technical risks are already validated
The integrated platform is new, but its core principles have been proven in separate operational settings.
Plug-n-play deployment assembled, installed and wet-tested at a customer facility.
Closed-operation cell culture run successfully in a warehouse, setting a sterility-duration record for the customer.
Full tech stack mapped, with 5 core provisional patents filed.
Techno-economic analysis confirms capex and opex savings.
Better economics grow the 2035 market from $90B to $500B
Serviceable addressable market, 2035.
Markets we unblock
- Dairy proteins (casein, lactoferrin, whey), HMOs
- Egg, algae and myco-proteins
- Cultivated meat and seafood
- Cultivated collagen, fat and oil
- Jet fuel, bioplastic monomers, textiles, specialty chemicals
- Flavors, pigments, probiotics, sweeteners, nutraceuticals
- Plant cell culture products
- Biostimulants, biopesticides, bioherbicides, biofertilizers
Climate impact based on the additional $410B of market over the current projection.
Support at every stage of scale-up
Guide development
TEA/LCA tools to steer process development toward commercial economics.
Move faster
Plug-and-play, scalable equipment for faster bench-to-pilot transitions.
Build the plant
End-to-end platform strategy, equipment and commissioning support.
Hyperscale
A hyperscaling-ready platform for commodity biomanufacturing.
We work only in the B2B middle of the value chain. We don't develop proprietary strains, cell lines or consumer products, so we never compete with our partners.
Built by a bioprocess operator and company builder
Zheng Huang, Ph.D.
- 20+ years of bioprocessing and industrial manufacturing experience
- Former Ark Biotech CTO: built a market-validated bioprocess SaaS platform in 24 months and took a first-of-a-kind 1,000L bioreactor from idea to field operation in 18 months
- Former Sanofi technical leader, supporting a multibillion-dollar U.S. manufacturing portfolio across 10 commercial products and 5 sites
- Deep-tech entrepreneur with 6 issued patents and 5 provisionals in the past four years
Let's make bio-made products profitable
Whether you're developing a bio-based product, running a CDMO or investing in the bioeconomy, we'd like to hear from you.
zheng@unblokbio.comZheng Huang, Ph.D. · Founder & CEO · Unblok Bioprocess, Inc.